Dp412e:a novel human embryonic dystrophin isoform induced by BMP4 in early differentiated cells by Massouridès, Emmanuelle et al.
RESEARCH Open Access
Dp412e: a novel human embryonic
dystrophin isoform induced by BMP4 in
early differentiated cells
Emmanuelle Massouridès1*, Jérôme Polentes1, Philippe-Emmanuel Mangeot2,3,4,5,6, Virginie Mournetas7,8,
Juliette Nectoux9, Nathalie Deburgrave9, Patrick Nusbaum9, France Leturcq9, Linda Popplewell10, George Dickson10,
Nicolas Wein11, Kevin M. Flanigan11, Marc Peschanski7,8, Jamel Chelly12 and Christian Pinset7,8
Abstract
Background: Duchenne muscular dystrophy (DMD) is a devastating X-linked recessive genetic myopathy. DMD
physiopathology is still not fully understood and a prenatal onset is suspected but difficult to address.
Methods: The bone morphogenetic protein 4 (BMP4) is a critical signaling molecule involved in mesoderm
commitment. Human induced pluripotent stem cells (hiPSCs) from DMD and healthy individuals and human
embryonic stem cells (hESCs) treated with BMP4 allowed us to model the early steps of myogenesis in normal and
DMD contexts.
Results: Unexpectedly, 72h following BMP4 treatment, a new long DMD transcript was detected in all tested hiPSCs
and hESCs, at levels similar to that found in adult skeletal muscle. This novel transcript named “Dp412e” has a
specific untranslated first exon which is conserved only in a sub-group of anthropoids including human. The
corresponding novel dystrophin protein of 412-kiloDalton (kDa), characterized by an N-terminal-truncated actin-
binding domain, was detected in normal BMP4-treated hiPSCs/hESCs and in embryoid bodies. Finally, using a
phosphorodiamidate morpholino oligomer (PMO) targeting the DMD exon 53, we demonstrated the feasibility of
exon skipping validation with this BMP4-inducible hiPSCs model.
Conclusions: In this study, the use of hiPSCs to analyze early phases of human development in normal and DMD
contexts has led to the discovery of an embryonic 412 kDa dystrophin isoform. Deciphering the regulation
process(es) and the function(s) associated to this new isoform can contribute to a better understanding of the
DMD physiopathology and potential developmental defects. Moreover, the simple and robust BMP4-inducible
model highlighted here, providing large amount of a long DMD transcript and the corresponding protein in only 3
days, is already well-adapted to high-throughput and high-content screening approaches. Therefore, availability of
this powerful cell platform can accelerate the development, validation and improvement of DMD genetic therapies.
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Background
The Duchenne muscular dystrophy (DMD) gene
(ENSG00000198947; MIM 300377) is located on the
X chromosome spanning more than two million base
pairs [1, 2]. Three promoters have been described
to drive expression of full-length 427-kiloDalton
(kDa) dystrophin isoforms: the muscular (dystrophin
protein 427 kDa muscular (Dp427m)), the cerebral (dys-
trophin protein 427 kDa cerebral (Dp427c)), and the pur-
kinje (Dp427p1/p2), each of which has a specific exon 1.
Other DMD transcripts and isoforms are expressed due to
alternative promoters and splicing with specific pattern of
expression along the development [3–7].
Mutations in the DMD gene cause Duchenne
(MIM 310200) and Becker (MIM 300376) muscular
dystrophies (BMD). While the majority of DMD patients
have no dystrophin, resulting in a severe phenotype,
milder BMD patients are characterized by expression of
dystrophin proteins abnormal in quantity and/or size. The
first symptoms of DMD usually appear between the ages
of 2 and 5 years [8, 9]. Progressive muscle weakness typic-
ally leads to wheelchair dependency by the age of 12 years.
Historically, death occurred before age 20 due to cardiac
and respiratory failure, but with improved care, life
expectancy has risen well into the third decade. Until
now, there is no curative treatment but there are several
therapeutic approaches in progress [10–14].
Since its first description in the mid-1800s [15], DMD
physiopathology is not fully understood. Interestingly,
analyses of X-linked muscular dystrophy (mdx) mice—a
dystrophin-deficient model—showed that the onset of
pathology can already be observed in utero with abnor-
mal myogenesis [16]. The importance of dystrophin
before birth was also demonstrated in sapje zebrafish
embryos, in which the absence of dystrophin induced
muscle attachment failure [17]. Furthermore, in golden
retriever muscular dystrophy dog puppies (aged 1–8 days),
lesions were particularly present in the most active
muscles in utero and during the neonatal period [18].
Histological studies on human DMD fetuses also indi-
cated that DMD consequences already appear in utero, with
fiber diameter variability, hyaline fibers, and increased
muscle nuclear size [19–21]. In line with these studies,
serum creatine kinase level is already elevated at birth in
DMD newborns [9, 22]. Interestingly, when mental retard-
ation was associated with DMD, a disorganized cellular
architecture was observed in post-mortem brains [23]
suggesting that dystrophin could be critical for the brain
development in utero. Moreover, a study on skeletal muscle
from presymptomatic DMD patients (aged 1.5–22 months)
in which the dystrophin protein was absent showed that
the gene expression profile is altered [24]. The highlighted
modifications in these DMD patients mostly resemble the
alterations previously described in advanced stages of the
disease indicating that, even without clinical symptoms,
DMD is already developing during the first months of life.
Taken together, these studies suggest that absence of
dystrophin has already consequences at early stages of
development. Due to technical and regulatory issues for
the research on human embryos and fetuses, we decided
to further address this question by producing human
induced pluripotent stem cells (hiPSCs) [25] from
healthy and DMD muscular cells. To compare the two
genetic contexts during the early steps of myogenesis,
we used a member of the transforming growth factor
beta (TGF-β) superfamily, bone morphogenetic protein
4 (BMP4) involved in mesoderm commitment [26–29].
Interestingly, BMP4 induced the expression of a long
DMD transcript in early mesoderm precursors derived
from either DMD/normal hiPSCs or normal human
embryonic stem cells (hESCs). This transcript is charac-
terized by a novel exon 1 conserved only in a sub-group
of anthropoids. The corresponding N-truncated protein,
also expressed in embryoid bodies (EBs), has the same
apparent molecular weight as a recently identified highly
functional dystrophin [30, 31]. Future studies of this new
human embryonic 412 kDa dystrophin isoform will con-
tribute to a better understanding of DMD physiopathology.
In addition, we demonstrated using a phosphorodiamidate
morpholino oligomer (PMO) targeted to skip the DMD
exon 53 that this robust BMP4-inducible hiPSCs model,
providing large amount of a long DMD transcript and the
corresponding protein, can be an efficient tool to accelerate
the development of DMD genetic therapeutic approaches.
Methods
Ethics, consent, and permissions
All healthy individuals and DMD patients had written
an informed consent before the biopsy procedure.
At the Cochin Hospital-Cochin Institute, the collec-
tion of primary cultures of myoblasts was established
from patient muscle biopsies conducted as part of med-
ical diagnostic procedure of neuromuscular disorders.
For each patient included in this study, signed informed
consent was obtained to collect and study biological re-
sources, and establish primary cultures of fibroblasts and
myoblasts at the Hospital Cell Bank-Cochin Assistance
Publique—Hôpitaux de Paris (APHP) . This collection
of myoblasts was declared to legal and ethical author-
ities at the Ministry of Research (number of declar-
ation, 701, n° of the modified declaration, 701–1) via
the medical hosting institution, APHP, and to the
“Commission Nationale de l’Informatique et des Liber-
tés” (CNIL) (number of declaration, 1154515).
The BMD muscle biopsy was carried out in accord-
ance with the ethical rules of the institutions involved
under approvals of the Nationwide Children’s Hospital
Institutional Review Board.
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Cell culture
Human adult myoblasts from healthy individuals and
DMD patients were provided by Celogos and Cochin
Hospital-Cochin Institute (Additional file 1: Table S1). In
Celogos laboratory, cell preparation was done according to
patent US2010/018873 A1.
Cells were maintained in a myoblast medium: DMEM/
F-12, HEPES (31330–038, Thermo Fisher Scientific,
MA, USA) supplemented with 10 % fetal bovine serum
(FBS, Hyclone, Logan, UT), 10 U/mL penicillin/strepto-
mycin (15140122, Thermo Fisher Scientific) on 0.1 %
gelatin (G1393, Sigma-Aldrich®, St. Louis, MO, USA)
coated cultureware with 10 ng/mL fibroblast growth
factor 2 (FGF2) (100-18B, Peprotech, Rocky Hill, NY),
and Dexamethasone 50 nM (D4902, Sigma-Aldrich®).
For hiPSCs generation, plasmid MSCV-IRES-GFP
(pMIG) vectors containing complementary deoxyribo-
nucleic acids (cDNAs) of v-myc avian myelocytomatosis
viral oncogene homolog (C-MYC), POU class 5 homeo-
box 1 or OCT-4 (POU5F1), SRY (sex determining region
Y)-box 2 (SOX2), and Kruppel-like factor 4 (KLF4) were
kindly provided by George Q. Daley [32]. These plas-
mids were individually transfected using Lipofectamine®
2000 (11668–027, Thermo Fisher Scientific) into plat-
inum (PLAT)-A packaging cells (for amphotropic retro-
viral production, RV-102, Cell Biolabs, San Diego, CA)
in a biosafety level 3 laboratory or PLAT-E packaging
cells (for ecotropic retroviral production, RV-101, Cell
Biolabs) in a biosafety level 2 laboratory. PLAT cells
medium was replaced 24 h post-transfection: Dulbecco’s
modified Eagle medium (DMEM), high glucose, Gluta-
MAX™ (31965023), pyruvate sodium 1 mM (11360–
039), β-mercaptoethanol 50 μM (31350–010) (Thermo
Fisher Scientific), and 10 % FBS (Hyclone).
At the same time, myoblasts were thawed and seeded
at 1 × 105 cells/cm2 in a 6-well plate.
One day after seeding, myoblasts for ecotropic repro-
gramming were treated for 1 h with murine cationic
amino acid transporter-1 (mCAT-1) gesicles 2.5 × 10−2
μg/μL final concentration [33], in 500 μL/well of fresh
myoblast medium. Viral supernatants were collected
48 h post-transfection, filtered through a 0.45-μm filter
(146561, Dutscher SA, Brumath, France), and mixed at a
1:1:1:1 ratio in a tube already containing Polybren (4 μg/
mL final concentration, H9268, Sigma-Aldrich®) and
Hepes (0.01 M final concentration, 15630056, Thermo
Fisher Scientific). One milliliter of this mix was added to
each well of mCAT-1 gesicles-treated myoblasts.
The medium was changed the following day. Four days
post-transduction, myoblasts were passaged and seeded
at three densities, 1.5 × 104, 3 × 104, and 6 × 104 cells/cm2,
on feeder layers of Zenith CF1 MEF (ZFVC-001, IVF
Online, Toronto, Canada), mitomycin-C (M4287,
Sigma-Aldrich®) treated. After 24 h, reprogrammed
myoblasts were shifted in “hESCs medium”: Knockout™
DMEM (10829–018), 20 % KnockOut™ Serum Replacement
(10828–028), 1X MEM Non-Essential Amino Acids Solu-
tion (11140–035), 50 μM β-mercaptoethanol (31350–010),
2 mM GlutaMAX™ Supplement (35050–038), and 10 U/
mL penicillin/streptomycin (15140–122) (Thermo Fisher
Scientific), 10 ng/mL FGF2 (Peprotech), supplemented with
0.5 mM valproic acid (P4543, Sigma-Aldrich®) during
10 days, with medium change every 2 days.
Human myoblasts for amphotropic reprogramming
were transduced by the amphotropic retrovector mix for
24 h. They were then passaged and seeded in myoblast
medium at 3.4 × 103 cells/cm2 per well in 0.1 % gelatin-
coated 6-well plates. The following day, the repro-
grammed myoblasts were shifted to hESCs medium with
valproic acid treatment during 10 days and medium
change every 2 days.
The hiPSCs colonies were picked between day 15 and
day 40 after transduction. They were subsequently
expanded with manual passages as clumps and main-
tained on mitomycin-C treated mouse embryonic fibro-
blasts (MEFs) in hESCs medium. StemMACS™ Y27632
(130-103-922, Miltenyi biotech, Bologna, Italy) was used
at 10 μM to increase the seeding efficiency of hiPSCs for
the initial colony expansion after picking, for the first
passage and at thawing.
Human iPSCs and ESCs (Additional file 1: Table S1)
were harvested for banking in single cell with StemPro®
Accutase® (A11105-01, Thermo Fisher Scientific) and
froze in Cryostor® CS10 (210102, BioLife Solutions, Inc.,
Bothell, WA).
Before our experiments, all hiPSCs and hESCs were
adapted and maintained with mTeSR™1 culture medium
(05850, Stemcell Technologies, Vancouver, Canada) on
Corning® Matrigel® Basement Membrane Matrix, lac-
tose dehydrogenase elevating virus (LDEV)-Free-coated
cultureware (354234, Corning Incorporated, NY, USA).
For adaptation of hiPSCs and hESCs to mTeSR™1
culture system (05850, Stemcell Technologies), cells
were thawed on mitomycin-C treated MEFs in mTeSR™1
medium (05850, Stemcell Technologies) with 10 μM
StemMACS™ Y27632. After 6 days, the adaptation
consisted of three successive passages on Corning®
Matrigel®-coated (354234) cultureware with several dif-
ferentiation removal steps. The cells were first passaged
with collagenase type IV (7909, Stemcell Technologies),
then with dispase (1 U/mL, 7923, Stemcell Technologies)
and finally in single cell with StemPro® Accutase®
(A11105-01, Thermo Fisher Scientific) with an average of
5 days between each passage. At this step, cells must be
mainly undifferentiated to be successfully adapted to
mTeSR™1 culture system (05850, Stemcell Technologies)
and to be banked. Cells were then seeded, passaged and
thawed each time with 10 μM StemMACS™ Y27632.
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We used for Fig. 1a the AnalySIS getIT 5.1 soft-
ware with an Olympus CKX41 microscope and SC30
digital camera.
Cell treatments
Pluripotent stem cells were thawed on Corning®
Matrigel®-coated (354234) cultureware in mTeSR™1
(05850, Stemcell Technologies) with 10 μM Stem-
MACS™ Y27632. When the cells were close to 70 %
confluence, they were passaged and seeded at 4 × 104
cells/cm2 with 10 μM StemMACS™ Y27632, with or
without recombinant human BMP4 (314-BP-050,
R&D Systems, Minneapolis, MN) at a final concentra-
tion of 5 ng/mL. Collections of RNAs or proteins
were done without any further medium change. The
medium was changed at day 4 only for collections
between days 5 and 7.
Recombinant human noggin (NOG, 120-10C, Peprotech)
was added for BMP4 inhibition at the seeding step
at 100 ng/mL final concentration, 1 h prior BMP4
addition.
For Activin A treatment, after seeding of human
pluripotent stem cells (hPSCs) as described above for
BMP4 treatment, Activin A was added at 10 ng/mL
(120–14; Peprotech).
RNA purification and qRT-PCR
After harvesting pluripotent stem cells using StemPro®
Accutase® (A11105-01, Thermo Fisher Scientific) and myo-
blasts/myotubes with Trypsin-ethylenediaminetetraacetic
acid (EDTA) (25300–054, Thermo Fisher Scientific), cell
pellets were resuspended in 350 μL of lysis buffer contain-
ing guanidine isothiocyanate (RLT) (79216, Qiagen, Hilden,
Germany) and stored at −80 °C. Total RNA were extracted
and purified according to either the RNeasy Mini Kit or
Micro Kit protocol (74104 and 74004, Qiagen). Several hu-
man RNAs were used for the dystrophin protein 412 kDa
embryonic (Dp412e) expression study (Testis 636533;
Ovary 636555; Fetuses, 636185; Master Panel II, 636643;
Cerebellum, 636535; Cerebral cortex 636561; Fetal heart,
636583; Smooth muscle, 636547; Heart, 636532; Skeletal
muscle, 636534; Clontech, Palo Alto, CA). Muscle RNA
from healthy individual biopsy was provided by Cochin
Hospital-Cochin Institute.
RNA level and quality were checked using a Nano-
drop spectrophotometer (ND-1000, Thermo Fisher
Scientific Inc., USA). For each sample, 500 ng of total
RNA were reverse transcribed with random primers
(48190–011), oligo(dT) (SO131), and deoxynucleotide
(dNTP) (10297–018) using Superscript® III reverse
transcriptase (18080–044) (Thermo Fisher Scientific).
Thermocycling conditions were 10 min, 25 °C; 60 min,
55 °C; and 15 min, 75 °C.
We amplified for quantitative real-time polymerase chain
reaction (qRT-PCR) these cDNA using primers (Thermo
Fisher Scientific) listed in Additional file 2: Table S2.
They were designed using Primer 3 (http://primer3.ut.ee)
[34], Primer blast (http://www.ncbi.nlm.nih.gov/tools/pri
mer-blast) and amplifX (v1.5.4, by Nicolas Jullien; CNRS;
Aix-Marseille University; http://crn2m.univ-mrs.fr/pub/
amplifx-dist). The amplification efficiency of each primer
set (except for QT primer and Dp412e forward primer)
was preliminarily determined by running a standard curve.
Detection was performed using a QuantStudio™ 12K Flex
Real-Time PCR System (Thermo Fisher Scientific).
Reactions were carried out in a 384-well plate, with 10 μL
containing diluted cDNA and primers, as well as
Luminaris Color HiGreen qPCR Master Mixes Low Rox
(K0973, Thermo Fisher Scientific Inc.). Thermocycling
conditions were 50 °C during 2 min, 95 °C during 10 min,
followed by 45 cycles including 15 sec at 95 °C, 1 min at
60 °C plus a dissociation stage. All samples were measured
in triplicate.
Protein isolation and Western blot analyses
After three rinses with cold PBS 1X (w/o Ca2+ and Mg2+,
D8537, Sigma-Aldrich®), protein extracts were isolated from
cultured cells by scraping (010154, Dutscher) with an ex-
traction protein buffer (75 mM Tris–HCl pH 6.8, 15 % so-
dium dodecyl sulfate (SDS), 5 % β-mercaptoethanol, 20 %
glycerol, 4 × 10−4mg/μL bromophenol blue, Protease Inhibi-
tor Cocktail diluted 1:100 (P8340, Sigma-Aldrich®), Phos-
STOP tablet (04906845001, Roche Diagnostics Corp.,
Indianapolis, USA)). Protein extracts were then heated once
5 min at 95 °C. Depending on the viscosity of the protein
extract, additional protein extraction buffer was needed for
some samples before a second and sometimes a third step
of 5-min heating. Protein Extracts were centrifuged 7 min
at 16,000 g, and supernatants were kept at −80 °C. Muscle
protein extracts from healthy individual biopsy were pro-
vided by Cochin Hospital-Cochin Institute. The Western
blots were performed for dystrophin detection with Criter-
ion™ XT Tris-Acetate Precast Gels 3–8 % (345-0129/
30, Bio-Rad, Hercules, CA) and XT Tricine running
buffer (161–0790, Bio-Rad). Samples were run at
room temperature (RT) for 1 h and 15 min at 150 V
(except for samples in Fig. 3c: 2 h and 30 min at
150 V with running buffer replenishing after 1 h and
15 min) with HiMark™ Pre-Stained Protein Standard
(LC5699, Thermo Fisher Scientific). Gels were rinsed once
in water and blotted for 11 min with “high molecular
weight” program of TransBlot® Turbo™ transfer system
(Bio-Rad) using Trans-Blot®Turbo™ Midi Nitrocellulose
Transfer Packs (170–4159). Blots were blocked for 45 min
with 5 % non-fat dried milk (170–6404, Bio-Rad) in
phosphate-buffered saline tween (PBST) buffer (Phosphate-
buffered saline 1X tablets, P4417, Sigma-Aldrich®; 0.1 %
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Tween® 20, 28829.296, VWR, West Chester, PA) followed
by an overnight incubation at 4 °C under agitation with ei-
ther NCL-DYS1 Dy4/6D3 (RRID: AB_442080, Novo-
castra Laboratories, Newcastle, UK) 1:30 or Manex6
[35] kindly provided by Prof. Glenn Morris (MDA
Monoclonal Antibody Resource, Wolfson Centre for
Inherited Neuromuscular Disease, Oswestry, UK) 1:30,
Mandra1 clone 7A10 (exon 77; Developmental Studies
Hybridoma Bank (DSHB), Iowa City, IA) 1:10,
Manhinge4A clone 5C11 (exon 62; DSHB) 1:30,
Manex7374A clone 10A11 (exon 73–74; DSHB) 1:30,
Mandys19 clone 8F6 (exon 21; DSHB) 1:30, and
Mandys101 clone 7D12 (exon 40–41; DSHB) 1:30, in
5 % non-fat dried milk in PBST buffer. After PBST
rinses, horseradish peroxidase (HRP)-conjugated poly-
clonal rabbit anti-mouse (P0260, DAKO, Glostrup,
Denmark) 1:5000 was used as a secondary antibody
after DYS1 or ECL Anti-Mouse IgG, horseradish per-
oxidase-linked species-specific whole antibody from sheep
1:10,000 (NA931, GE Healthcare Life Sciences) after all
the other primary dystrophin antibodies in 5 % non-fat
dried milk in PBST, for 5 h at RT under agitation. The
blots were rinsed with PBST before immuno-reactive
bands were visualized using Amersham ECL Select
Western Blotting Detection Reagent according to the
manufacturer’s protocol (RPN2235, GE Healthcare Life
Sciences, Buckinghamshire, UK) and the ImageQuant
LAS 4000 mini system (GE Healthcare Life Sciences).
After DYS1 visualization, blots were rinsed in PBST and
stripped with Restore™ Western Blot Stripping buffer
(21059, Thermo Fisher Scientific) for 15 min at RT. After
additional PBST rinses, blots were blocked again and
incubated with mouse monoclonal anti-alpha Tubulin
antibody (DM1A) (ab7291, Abcam, Cambridge, UK)
1:2500 in 5 % non-fat dried milk PBST, during 1 h at RT
under agitation. After PBST rinses, ECL Anti-Mouse IgG,
horseradish peroxidase-linked species-specific whole anti-
body from sheep 1:10,000 (NA931, GE Healthcare Life
Sciences) was used as a secondary antibody in 5 % non-fat
dried milk PBST, for 1 h at RT under agitation. Amersham
ECL Prime Western Blotting Detection Reagent (RPN2232,
GE Healthcare Life Sciences) was used for immuno-
reactive bands visualization.
α-Tubulin detection was done either after DYS1 for the
blots on Fig. 3, in Additional file 3: Figure S5a and
Additional file 4: Figure S6b or in parallel to DYS1 and
other dystrophin antibodies for all the other blots pre-
sented in this study by cutting the membranes before pri-
mary antibody incubation.
Western blots were performed for Phospho-small
mothers against decapentaplegic (SMAD)1/5 detection
with Criterion™ TGX™ Precast Gels 4–15 % (5671084,
Bio-Rad) and Tris/Glycine/SDS running buffer (1610772,
Bio-Rad). Samples were run at RT for 55 min at 200 V.
Gels were rinsed once in water and blotted for 7 min with
“mixed MW” program of TransBlot® Turbo™ transfer
system (Bio-Rad).
Blots were blocked for 1 h with 5 % non-fat dried milk
in tris-buffered saline tween (TBST) buffer at RT
(137 mM NaCl, 20 mM Tris pH 7.6, 0.1 % Tween® 20
(28829.296, VWR)) followed by an overnight incubation
at 4 °C under agitation with Phospho-SMAD1/5 anti-
body (Ser463/465, 41D10; 9516P, Cell Signaling, Beverly,
MA) 1:1000 in 10 % bovine serum albumin (BSA) TBST.
After TBST rinses, ECL Anti-Rabbit IgG, HRP-linked
(NA934, GE Healthcare Life Sciences) 1:10,000 was used
as a secondary antibody in 5 % non-fat dried milk TBST,
for 1 h at RT under agitation. The blots were rinsed with
TBST before immuno-reactive bands visualization with
Amersham ECL Prime. α-Tubulin detection was then
done after a stripping step (see above).
Quantification showed in Additional file 4: Figure S6c
was done with the ImageQuant TL 7.0 software.
5′RACE PCR
Characterization of transcripts by rapid amplification of
cDNA 5′ ends (5′RACE) polymerase chain reaction
(PCR) was performed using the SMARTer® RACE cDNA
Amplification Kit (634923, Clontech) according to the
manufacturer instructions. RNA of the precursors
derived from hiPSCs 1 3 days after BMP4 treatment was
used for this purpose. Briefly, integrity of purified RNAs
was checked upon migration in an agarose gel stained
with Ethidium Bromide. RNA (500 ng) was used as a
template to produce the RACE-ready cDNAs whose 5′
extremities are modified to incorporate the Universal
Primer (UPA) sequence. A first round of cDNA amplifica-
tion was performed using a first set of primers (Forward:
UPA long: 5′-CTAATACGACTCACTATAGGGCAAGC
AGTGGTATCAACGCAGAGT-3′, Reverse: DP427R1: 5′
-TGTAGGTCACTGAAGAGGTTCTCAA-3′ correspond
ing to a region in the third exon of DMD cDNA). Prod-
ucts of amplification were next amplified by nested
primers (Forward: NUPA: 5′-AAGCAGTGGTATCAA
CGCAGAGT-3′, Reverse: DP427R2: 5′-TGTGCATTTAC
CCATTTTGTG-3′ corresponding to a region in the
second DMD exon). To increase the specificity of the
RACE assay, priming of cDNAs synthesis was also
achieved using a DMD-specific primer in the fourth exon
(Ex4R1: 5′-GGGCATGAACTCTTGTGGAT-3′) instead
of the polyT primer included in the SMARTer® RACE
cDNA Amplification Kit. cDNAs obtained with this modi-
fied protocol were next amplified by primers Forward:
UPA long: 5′-CTAATACGACTCACTATAGGGCAAGC
AGTGGTATCAACGCAGAGT-3′, Reverse: 602Rex3:
5′-GGTCTAGGAGGCGCCTCCCATCCTGTAG-3′),
followed by a nested PCR using Forward: NUPA: 5′-
AAGCAGTGGTATCAACGCAGAGT-3′, Reverse: 60
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3Rexnew: 5′-TCCACACCAGGTGGGGACGGATGA
CCT-3′ corresponding to Dp412e exon 1.
Amplicons from the nested PCRs were finally cloned
using the Zero Blunt® PCR cloning kit (K2700-20,
Thermo Fisher Scientific) prior sequencing (GATC
Biotech, Konstanz, Germany). Overlapping reads were
assembled into contigs mapped on the DMD gene.
Immunolabeling
After 4 days with or without BMP4 treatment, slides for
immunolabeling were prepared with the Thermo Scientific™
Cytospin™ 4 Cytocentrifuge. Briefly, cultures were washed
once with PBS 1X (P4417, Sigma-Aldrich®), and StemPro®
Accutase® (A11105-01, Thermo Fisher Scientific) was added
for 5 min at 37 °C. The cells were harvested and transferred
in a 15-mL tube, and the enzyme was diluted in
DMEM/F-12, HEPES (31330–038, Thermo Fisher
Scientific). Cells were counted and resuspended at
400,000-cells/mL concentration. Five hundred microliter
of the cell suspension were loaded in each Shandon cytos-
pin® centrifuge funnels, such as a spot of 200,000-cells was
available on each superfrost® plus slide (631–0108, VWR)
at the end of the centrifugation cycle (900 rpm, 4 min).
Cells were immediately fixed with 4 % paraformaldehyde
(15710, Euromedex, Souffelweyersheim, France) for
10 min at RT and then washed three times in PBS 1X for
15 min each.
Cell spots were delimited for immunolabeling with a
PAP pen (Z672548-1EA, Sigma-Aldrich®) and then
permeabilized with PBS 1X containing 0.3 % Triton™
X-100 (T8787, Sigma-Aldrich®) for 30 min at RT. In-
cubation with pure NCL-DYS1 Dy4/6D3 (Novocastra
Laboratories) was performed overnight at 4 °C, then
slides were washed three times with PBS 1X for
30 min each wash. Incubation with a mix of Dylight
549-conjugated AffiniPure F(ab′)2 fragment Goat
Anti-Mouse IgG (H+L) (1:1000; 115-506-003, Jackson
ImmunoResearch laboratories Inc., PA, USA) and
DAPI (1:2000; 268298, Calbiochem, La Jolla, CA) was
done for 30 min at RT. Slides were finally washed
three times with PBS 1X (30 min/wash) and mounted
with fluoromount (F4680; Sigma-Aldrich®). Observation
and image captures were done on an AxioObserver Z1
Zeiss microscope with Zen Blue software (Carl Zeiss
Microscopy GmbH, Jena, Germany).
For Fig. 3d, 40 % of brightness were added in Microsoft®
PowerPoint® 2010 after the TIFF image insertion of
hiPSCs 1 and DMD hiPSCs 2.
PCR and TaqMan® arrays analyses
TaqMan® Array Human Stem Cell Pluripotency Panel
(4385344, Thermo Fisher Scientific) was used to investi-
gate the differentiation status of BMP4-treated hiPSCs 1
at day 3 as compared to untreated hiPSCs 1. According
to TaqMan® Array protocol (Thermo Fisher Scientific),
instead of 500 ng, we used 1500 ng of total RNA for
each sample to do the reverse transcription (for details,
see “RNA Purification and qRT-PCR” paragraph above).
Each cDNA sample was mixed with 2X TaqMan® Gene
Expression Master Mix (4369016, Thermo Fisher Scien-
tific) and distributed in triplicates on the TaqMan® ar-
rays. qRT-PCR were performed on an Applied
Biosystems 7900HT Fast Real-Time PCR System (2 min,
50 °C; 10 min, 95 °C; 40X (15 s, 95 °C; 60 s, 60 °C)), and
raw data were formatted to be analyzed using the online
SAbioscience tool.
TGF-β/BMP signaling pathway study was performed
using 384 wells RT2 Profiler Plus PCR Array (PAHS-
035YE, Qiagen) according to the Qiagen Handbook.
After total RNA isolation using RNeasy Mini kit (74104,
Qiagen), 500 ng of RNA for each sample were treated
with Buffer GE (Qiagen; 5 min, 42 °C) to eliminate gen-
omic DNA. Purified RNAs were then reverse transcribed
using the RT2 First Strand Kit (330401, Qiagen; 5X
Buffer BC3, Control P2, RE3 Reverse Transcriptase Mix;
15 min, 42 °C then 5 min, 95 °C). Each cDNA sample
was complemented with Qiagen 2X RT2 SYBR Green
Mastermix (330521, Qiagen) and distributed in quadru-
plicates in the PCR arrays.
Three samples were tested at day 3: hiPSCs 1 without
treatment, after BMP4, or NOG + BMP4 treatment. Ana-
lyses (ΔCt, ΔΔCt, Fold Change, statistical analyses) were
performed using the online SAbioscience tool associated
to the RT2 PCR arrays (http://pcrdataanalysis.sabioscien
ces.com/pcr/arrayanalysis.php).
Embryoid bodies
We used the Stemcell Technologies protocol to pro-
duce embryoid bodies (EBs). Briefly, pluripotent stem
cells were thawed on Corning® Matrigel®-coated
(354234) flasks in mTeSR™1 (05850, Stemcell Tech-
nologies) with 10 μM StemMACS™ Y27632. When the
cells were close to 70 % confluence, they were har-
vested using StemPro® Accutase® (A11105-01, Thermo
Fisher Scientific) and resuspended in AggreWell™
medium (05893, StemCell Technologies) supple-
mented with 10 μM StemMACS™ Y27632 and finally
seeded on AggreWell™ TM800 culture plates (27865,
Stemcell Technologies). According to the StemCell
procedure, three million cells were thus distributed
on each well to form a maximum of 300 EBs with
10,000 cells per EB. EBs were maintained in Aggre-
well plates during the whole culture duration to avoid
EBs fusion and to preserve a homogenous differenti-
ation. Half of the culture media was gently replaced
every 2 days. For BMP4 treatment, BMP4 was added
directly in Aggrewell™ medium at EBs seeding (30 ng/
mL) and every medium change. To harvest EBs, the
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whole culture medium of a well was pipetted up and
down, transferred to a 40 μm strainer (352340,
Dutscher) to eliminate any single cell, and each well
was washed twice with DMEM/F-12, HEPES (31330–
038, Thermo Fisher Scientific). EBs were then transferred
to a new tube with DMEM/F-12, HEPES, centrifuged
5 min at 300 g, resuspended in buffer RLT (79216, Qia-
gen) or protein extraction buffer (see “Protein isolation
and Western Blot analyses” section), and stored at −80 °C
for subsequent analyses.
Exon skipping
Two days after induction, BMP4-treated hiPSCs 1
were transfected by electroporation with a phosphoro-
diamidate morpholino oligomer (PMO) targeting exon
53 of the DMD gene, based on previously published
data [36] at 1, 10, or 100 μM with 200,000 cells in
20 μL solution from the P3 Primary Cell 4D-
Nucleofector® X Kit (V4XP-3032, Lonza, Basel,
Switzerland) using the CB150 program on the 4D-
Nucleofector™ System (Lonza). RNA extraction was
carried on transfected cells 24 h later followed by re-
verse transcription as described above. PCR was done
on 250 ng cDNA using forward and reverse primers
(Fw 5′-TTACCGACTGGCTTTCTCTGC-3′ and Rv
5′-GTCTGCCACTGGCGGAGGTC-3′, Thermo Fisher
Scientific) and Taq DNA polymerase (10342, Thermo
Fisher Scientific) as described by the manufacturer’s
instructions, for a final reaction volume of 50 μL.
PCR reaction started by a step at 94 °C for 3 min,
followed by 35 cycles at 94 °C for 45 s, 55 °C for
45 s and 72 °C for 45 s, and a final step at 72 °C for
5 min. Exon skipping was analyzed using the DNA
1000 kit (5067, Agilent, Santa Clara, CA, USA) on
the Agilent 2100 Bioanalyzer. Full-length PCR prod-
uct was 460 bp and exon skipped length PCR prod-
uct was 248 bp. Results are displayed as a gel-like
image and computed by the Agilent 2100 Bioanalyzer soft-
ware v3.81.
Statistical analyses
Except for the PCR arrays, all statistical analyses were
done with JMP® (v9.0.2). We used Wilcoxon’s test for
qRT-PCR analyses. No statistical difference was found
between DMD hiPSCs and normal hPSCs at day 0 and
every day after BMP4 induction until day 4. Therefore,
DMD patients and healthy individuals were analyzed
together for this study. Exceptionally, BMP4-treated
DMD hiPSCs 2 sample was removed from the analysis
of the primer set specific to exons 20–21, as we did not
detect any DMD expression due to the patient genetic
mutation.
Results
BMP4-treated human pluripotent stem cells express
mesoderm markers
BMP4 was used to induce differentiation toward mesoder-
mic lineage of human pluripotent stem cells lines (hPSCs;
including hiPSCs and hESCs; Additional file 1: Table S1).
When hPSCs without BMP4 treatment started to form
compacted colonies, BMP4-treated hPSCs formed a con-
fluent layer with a more flattened morphology (Fig. 1a).
TaqMan® Array showed, on BMP4-treated hiPSCs 1,
the downregulation of pluripotency markers (e.g., SOX2,
POU5F1) and upregulation of markers specific to meso-
derm (e.g., T, EOMES, CDX2, ISL LIM homeobox 1
(ISL1), GATA binding protein 4 (GATA4), and actin,
alpha, cardiac muscle 1 (ACTC1)) or to endoderm (such
as SOX17) but none to ectoderm (such as paired box 6
(PAX6)) (Fig. 1b).
qRT-PCR, on all BMP4-treated hPSCs, confirmed the
downregulation of pluripotency markers (high for SOX2
and moderate for POU5F1; Fig. 1c) and upregulation of
mesodermic markers (Fig. 1d) that had been previously
identified (i.e., T, ISL1, GATA4, and ACTC1) or addition-
ally tested (i.e., paired-like homeodomain transcription
factor 2 (PITX2), Msh homeobox 1 (MSX1), PAX3, EYA
transcriptional coactivator and phosphatase 1 (EYA1),
actin, alpha 2, smooth muscle, aorta (ACTA2)).
BMP4-treated human pluripotent stem cells express a long
DMD transcript with a novel exon 1 conserved in a
sub-group of anthropoids
After BMP4 treatment, all the primers designed along
the DMD gene (Additional file 2: Table S2) demon-
strated the robust expression of long DMD transcripts in
all tested hPSCs, rising from day 1 to day 3, with high
levels comparable to the levels of Dp427m expressed in
normal adult skeletal muscle [37] (Fig. 2a). The differ-
ence of DMD transcript expression was statistically sig-
nificant for all primers from day 2 in comparison to
day 0 (exons 2–3, 310-fold, p < 0.0001; exons 20–21,
490-fold, p = 0.0002; exons 45–46, 54-fold, p < 0.0001;
exons 64–65, 2.7-fold, p < 0.0001). Higher fold changes
were always detected with the primers specific to the
5′-end (exons 2–3 and 20–21) compared to primers
targeting the 3′-end (exons 45–46 and 64–65), as has
already been described for Dp427m in normal muscles
from mouse [38] and human [30, 39].
BMP4-treated hiPSCs 1 and DMD hiPSCs 3 were fur-
ther analyzed to assess the DMD transcript expression
over time. In both cell lines, the expression of DMD tran-
scripts started to decrease from day 4 until day 7 and
almost returned to basal level (hiPSCs 1: day 3 = 200-fold,
day 7 = 7-fold; DMD hiPSCs 3: day 3 = 388-fold, day
7 = 6-fold; Additional file 5: Figure S1).
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Fig. 1 (See legend on next page.)
Massouridès et al. Skeletal Muscle  (2015) 5:40 Page 8 of 18
Specific primers for each known long DMD transcript
were then designed to identify the BMP4-induced DMD
transcripts. In BMP4-treated hPSCs, only a slight level
of Dp427c was detected as in normal adult skeletal
muscle (Fig. 2b). Dp427c expression was increased from
day 1 and started to decrease at day 4 (day 3 vs day 0,
3.3-fold, p = 0.0035). However, Dp427c upregulation was
too faint to explain the high level of DMD transcripts ob-
served previously. We then decided to use 5′RACE PCR
to identify a possible new transcript. Two main sequences
were recursively found (Additional file 6: Figure S2). The
first one was identified as the 164 last nucleotides of the
Dp427c exon 1, spliced to the first nucleotides of exon 2.
The second was a new sequence of 643 nucleotides (pos-
ition in chromosome X (chrX), 33101211–33101853;
(GenBank: KT072086)) spliced to the first nucleotides of
exon 2. A corresponding transcript was not yet described,
but a BLAST-like alignment tool (BLAT) analysis [40]
showed that this sequence of 643 nucleotides was intronic
and located 44.3 kb downstream of the dystrophin protein
Fig. 2 BMP4-treated hPSCs express a new transient long DMD transcript. a qRT-PCR of DMD transcripts using primers specific to exons 2–3, 20–21,
45–46, and 64–65. Black bars represent mean ± SD from nine hPSCs at days 0 through 4 after BMP4 treatment. A muscle biopsy from a healthy
individual was used as a control (white bar). Gene expression was normalized to mean of GAPDH and UBC and plotted (log10 scale) relative to
mean expression of all hPSCs at D0. b qRT-PCR of DMD transcripts using primers specific to exons 2–3, Dp427c, and the new DMD transcript.
On the left side, data represent the mean ± SD from nine hPSCs from days 0 through 4 after BMP4 treatment. On the right are data
from expression in cultured normal myoblasts and myotubes, as well as in muscle biopsied from a healthy individual. Gene expression was normalized
to mean of GAPDH and UBC and plotted (log10 scale) relative to mean expression of all hPSCs at D0. *p< 0.05, **p< 0.01, ***p< 0.001, and ns for not
statistically significant
(See figure on previous page.)
Fig. 1 BMP4 treatment induces mesoderm lineage markers in hiPSCs/hESCs. a Examples of morphology in hiPSCs 3 and DMD hiPSCs 1 at day 4
either without or after a single BMP4 treatment. Scale bar = 50 μm. b TaqMan® Human Stem Cell Pluripotency Array data showing 2-dCT of lineage marker
genes in hiPSCs 1 at day 3 either without or after a single BMP4 treatment. Genes selected for display showed a minimum of ±2 fold change on relative
quantifications (RQs) calculation in BMP4-treated hiPSCs 1, as compared to hiPSCs 1 without BMP4 treatment (p< 0.05; based on a Student’s t test). c and
d Quantitative RT-PCR of c pluripotency and d early mesoderm specific genes. Curves represent the mean ± SD (standard deviation) from nine pluripotent
stem cell lines (hPSCs) at days 0 through 4 after BMP4 treatment. Gene expression was normalized to the mean of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) and ubiquitin C (UBC) and plotted (log10 scale) relative to the mean expression of all pluripotent stem cells at day 0 (D0)
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427 kDa purkinje (Dp427p) exon1 and 62.9 kb upstream
of exon 2.
With primers specific to this new exon 1, we thus found
evidence that this new DMD transcript was expressed in
all BMP4-treated hPSCs but neither in normal adult myo-
blasts/myotubes nor in normal adult skeletal muscle
(Fig. 2b). The expression of this new DMD transcript rose
from day 1 to day 3 after BMP4 treatment (day 3 vs day 0,
633-fold, p < 0.0001).
Genomic conservation analysis on 100 vertebrate
species indicated that this new exon 1 sequence is only
found in a sub-group of anthropoids despite some
insertions and nucleotide substitutions between species
(Additional file 7: Figure S3a). Furthermore, upstream
and downstream of this new exon 1, there are sequences
of 1.1 kb (chrX 33,101,854-33,103,030) and 6.3 kb (chrX
33,094,869-33,101,210), respectively, conserved only in
these anthropoids despite gap regions in Marmoset,
Gibbon, and Baboon. Interestingly, this large conserved
sequence is composed of a long terminal repeat (LTR)
retroelement split by inserts of simple repeats and Alu
sequences (Additional file 7: Figure S3b). This LTR
retroelement includes the whole human endogenous
retrovirus-like sequence-Proline 1 (HuERS-P1) [41]
flanked by two almost identical LTR8.
The new long DMD transcript encodes an N-truncated
dystrophin protein
Due to our previous analyses, we assumed that the new
DMD transcript has the same sequence between exon 2
to 79 as the long known DMD transcripts. This theoret-
ical sequence was analyzed to study the possible trans-
lated proteins (Additional file 8: Figure S4). No open
reading frame appeared to be available from this new
exon 1. The first start codon (AUG) corresponding to a
methionine and allowing a long protein translation was
identified in the sixth exon (chrX 32834745), followed
closely thereafter by a second AUG in the same exon
(chrX 32834733). If translation starts at this first or sec-
ond AUG, the corresponding protein is predicted to be
about 412 kDa with an N-terminal truncated actin-
binding domain 1 (ABD1).
To investigate the presence of this protein, we decided
to perform Western blot analyses 4 days after BMP4
treatment (Fig. 3a and Additional file 3: Figure S5a). In
contrast to DMD hiPSCs, a protein just below 427 kDa
was easily detected in all other BMP4-treated hPSCs.
A kinetic analysis showed that this protein was
detectable as soon as day 2 after BMP4 treatment
(Additional file 3: Figure S5b), and antibodies specific
to several regions of the dystrophin protein confirmed
the detection of a high molecular weight protein
(Additional file 4: Figure S6a). Apart from Mandra1
antibody, they all demonstrated that this protein has
a molecular weight slightly smaller than 427 kDa in
comparison to the Dp427 long isoforms expressed in
muscle tissue.
Western blot analyses were then done on normal
BMP4-treated hPSCs to study the protein stability over
time (Fig. 3b and see Additional file 4: Figure S6b and S6c).
Apart from hESCs 1 and hiPSCs 2, at day 7 the dystrophin
protein was barely detectable in the BMP4-treated hPSCs.
In skeletal muscle of mild BMD patients with a variety
of mutations in the 5′ exons, a dystrophin protein with
a translation starting also at exon 6 was recently
described [30, 31]. Interestingly, one of these BMD
patients, with an exon 2 frameshift mutation leading to
an alternative translation initiation in exon 6 (Fig. 3c),
has the same apparent molecular weight than our
BMP4-induced dystrophin protein. Thus, the new dys-
trophin isoform described here is strongly suggested to
be translated from exon 6 and therefore will be hereafter
referred to as “Dp412e” (“e” standing for embryonic).
This dystrophin protein was also detected by im-
munofluorescence in BMP4-treated hiPSCs 1 but not
in BMP4-treated DMD hiPSCs 2, confirming Western
blot experiments (Fig. 3d). A large proportion of
BMP4-treated hiPSCs 1, after 4 days of treatment,
was positive for dystrophin staining.
BMP pathway activation is essential for Dp412e expression
PCR arrays were used to evaluate the impact of BMP4
treatment on signaling among the whole TGF-β super-
family, including the BMP pathway. They showed upreg-
ulation of BMP pathway actors, such as several ligands
(BMP2, 4, and 7), type I and II receptors (BMPR1A,
ACVR1A, and BMPR2, ACVR2A), SMAD1 and SMAD5,
SMAD4 and inhibitors (NOG, CHRD, BAMBI, SMAD6,
and 7; Fig. 4a). Concerning the TGF-β pathway, type I
receptor was upregulated but not type II. The Activin
pathway actors were also upregulated with SMAD2,
SMAD3, and the receptors cited above. However, 72 h
following Activin A treatment, unlike brachyury (T), a
specific mesoderm marker, Dp412e was not induced by
the Activin A pathway (Fig. 4b). Moreover, under this
condition, the level of SOX2 remained high while en-
dogenous BMP4 was not upregulated.
To confirm the BMP pathway activation, we investi-
gated the phosphorylation of SMAD1 and SMAD5, two
major proteins transducing extracellular signals. The
phosphorylated SMAD1 and SMAD5 were detected as
soon as 30 min after BMP4 addition, started to decrease
at day 2, and returned to basal level at day 4 (Fig. 4c).
To explore the relationship between BMP4, mesoderm
commitment and upregulation of Dp412e, noggin
(NOG), a natural antagonist of BMP4, was used 1 h
prior to BMP4 induction. In the presence of NOG, the
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BMP pathway actors mentioned above were not upregu-
lated except SMAD4 and SMAD7 (Fig. 4a) and no
Dp412e upregulation was detected (Fig. 4d). Other tran-
scripts (Fig. 4d), previously shown to be upregulated by
BMP4, were either slightly expressed (i.e., PAX3) or
stayed at basal level (i.e., T, PITX2, ISL1, ACTC1,
ACTA2, GATA4, and BMP4).
Dp412e is expressed in embryoid bodies
To define more precisely the expression profile of
Dp412e, RNAs from fetal/adult human tissues and
human fetuses were analyzed. While expression of
Dp427m and Dp427c was detected in expected tissues
(Additional file 9: Figure S7), Dp412e was upregulated in
BMP4-treated hiPSCs 1 but no significant expression
was detected in all other tested RNAs from fetal and
adult tissues.
As seeking Dp412e expression in an exhaustive collec-
tion of human embryos remains a difficult task, we decided
to study Dp412e profile in EBs. These aggregates of pluri-
potent stem cells mimic the early phases of development
through differentiation toward the three germ layers [42].
Dp412e transcripts were detected at low level between day
2 and day 10 of differentiation in hESCs 1 and hiPSCs 1
EBs (Fig. 5a). With BMP4 treatment, Dp412e expression
was strongly increased and was detected from day 1 at a
level similar to BMP4-treated hPSCs (Fig. 5a). A faint band
corresponding to Dp412e was detected by Western blot
from day 3 to day 14 in hESCs 1 and hiPSCs 1 EBs without
BMP4 treatment (Fig. 5b). As with Dp412e transcripts,
Fig. 3 BMP4-treated hiPSCs/hESCs express dystrophin protein. a Western blot in three pluripotent stem cell lines (hiPSCs 2, DMD hiPSCs 2, and hESCs 1)
at day 4 either without or after BMP4 treatment. b Western blot in hiPSCs 1 and hESCs 1 from days 3 through 7 following BMP4 treatment. c Western
blot analysis on protein extracts from hiPSCs 1 4 days after BMP4 treatment, from a BMD patient muscle biopsy with an exon 2 frameshift mutation
(c.40_41del (p.Glu14ArgfsX17)) and from normal skeletal muscle. d Immunolabeling of hiPSCs 1 and DMD hiPSCs 2, 4 days after BMP4 treatment. Scale
bar = 20 μm. (Dystrophin antibody: DYS1 (RRID: AB_442080) for Western blots and immunolabeling; muscle biopsy protein extract from a healthy
individual serves as a control; α-tubulin was used as loading control)
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Fig. 4 (See legend on next page.)
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a BMP4 treatment on hiPSCs 1 increased the Dp412e
protein level during the EB differentiation from day 3
to day 14 (Fig. 5c). Moreover, Dp412e was not detected
in DMD hiPSCs 2 EBs with or without BMP4 treat-
ment (Fig. 5b, c).
Exon skipping on BMP4-treated hiPSCs 1: a proof of
concept
The BMP4-treated hPSCs model provides an unlimited
quantity of cells expressing a large amount of Dp412e
transcript and the corresponding protein only 72 h
following BMP4 treatment. Furthermore, this fast, easy,
and robust cell platform is already adapted to high-
throughput and high-content screening approaches. As
we can study the protein rescue in a timescale of only a
week, this model could efficiently allow the validation and
the improvement of DMD genetic therapeutic approaches.
The exon-skipping strategy was chosen to do the proof
of concept, using a phosphorodiamidate morpholino
oligomer (PMO) targeting exon 53 based on previously
published data [36].
Three days after BMP4 treatment and 1 day after PMO
transfection on hiPSCs 1, a dose-dependent skipping
effect of the PMO 53 was observed. Indeed, no exon
skipping was detectable with 1 μM PMO, whereas nearly
10 % of the total amount of Dp412e had a skipped exon
53 with 10 μM and almost 58 % with 100 μM (Fig. 6).
Discussion
This study identifies a new long dystrophin isoform, herein
denominated “Dp412e”, specific to early stages of differenti-
ation induced by BMP4 in human pluripotent stem cells.
The specificity of this new DMD transcript is deter-
mined by a newly identified exon 1. Dp412e exon 1 and
its associated upstream/downstream sequences are
composed of simple repeats [43], Alu sequences [44, 45],
and a LTR retroelement [46]. This LTR retroelement
could be a relic of an ancient retrovirus infection over
40 million years ago in a common ancestor of the sub-
group of anthropoids highlighted here. The DMD gene
is known to have acquired new sequences and become
more complex during evolution [6, 47]. This notably
occurred at different stages of anthropoid evolution, as
demonstrated for the Dp412e exon 1 region, Dp427m
promoter with its upstream region, and for exon X and
exon 2a which have been described in DMD transcripts
[48–50]. Insertion in the human genome of Alu sequences
participate in gene regulation [51], and retroelements can
bring tissue-specific gene expression like for amylase in
parotid [52, 53] or new functional proteins like syncytins
in placenta [54, 55]. Retrovirus-like sequences can also
provide functional modules including enhancers, pro-
moters and splice sites [56], inducing the expression of
new sequences. The exon X supports the idea that
Dp412e exon 1 insertion in a DMD transcript could be
the result of this phenomenon, as it is also located in the
same retrovirus-like sequence HuERS-P1, 4.7 kb down-
stream of Dp412e exon 1.
Unlike the Dp412e exon 1 conservation in a sub-group
of anthropoids, a similar embryonic dystrophin protein
could be expressed in ancient species with a different
exon 1 sequence due to strong positive selection indu-
cing independent convergent evolution, as has been
shown with salivary amylase in mice and human, and
with syncytins in diverse mammalian species [52–54].
Moreover, our study indicates that the two first in-
frame AUGs in exon 6 are the starting point of the
Dp412e translation. The functionality of these AUGs has
already been explored in vitro using reporter constructs
[31]. Changing the first AUG to non-initiation codon
moderately decreased the translation yield whereas
changing the second AUG almost abrogated it. The
DMD transcript secondary structure, predicted in silico
(http://mfold.rna.albany.edu/?q=mfold/rna-folding-form),
could form a hairpin loop that brings these two AUGs
side by side; therefore, we can hypothesize that they are
closely related.
With a translation starting at exon 6, it implies that
the first five exons in the 5′-end are not translated.
To have one or several exons untranslated is not
uncommon, as shown for amylase [53], prolactin
receptor [57] and Dp140 [58]. The 5′-untranslated
region (5′-UTR) of Dp412e resembles that of the
Dp140 transcript, as the Dp140 exon 1 is also located
in an intron (the 44th) and its translation starts in
exon 51 [58].
For 5′-UTRs, one of the possible functions is the
internal ribosome entry site (IRES) allowing the
(See figure on previous page.)
Fig. 4 Correlation of BMP pathway activation with mesodermal commitment and Dp412e expression. a Microarray data showing 2-dCT of Human
TGF-β/BMP Signaling Pathway genes in hiPSCs 1 without or 3 days following a single BMP4 treatment or with addition of NOG prior to BMP4 treatment
(four technical duplicates/condition). Genes selected for display showed a minimum of ±2-fold change on RQs calculation in either BMP4-treated hiPSCs 1
or NOG/BMP4-treated hiPSCs 1, as compared to hiPSCs 1 without BMP4 treatment (p< 0.05; based on a Student’s t test). b Quantitative RT-PCR in hiPSCs 1
of Dp412e, BMP4, SOX2, and T expression after 3 days of BMP4 or Activin A treatment. Gene expression was normalized to peptidylprolyl isomerase A
or cyclophilin A (PPIA) and plotted (log10 scale) relative to the mean expression of hiPSCs 1 at day 3 without treatment (n = 2). c Western blot analysis
of phospho-SMAD 1/5 in hiPSCs 1 from days 0 through 4 after BMP4 treatment. α-Tubulin was used as loading control. d Quantitative RT-PCR in hiPSCs
1 of DMD transcripts with specific primers to exons 2–3, PAX3, T, PITX2, ISL1, ACTC1, ACTA2, GATA4, and BMP4 3 days after BMP4 treatment, with
or without Noggin (NOG) pre-treatment. Gene expression was normalized to GAPDH and plotted (log10 scale) relative to hiPSCs 1 at D0
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Fig. 5 Dp412e is expressed in embryoid bodies (EBs). a Quantitative RT-PCR of Dp412e transcripts in hiPSCs 1 and hESCs 1 EBs from day 0 to day
10 of differentiation with or without BMP4 treatment. Gene expression was normalized to PPIA and plotted (log10 scale) relative to each cell line con-
trol at D0. b Western blot analysis on hESCs 1, hiPSCs 1, and DMD hiPSCs 2 EBs from day 3 to day 14 without BMP4 treatment. c Western blot analysis
on hiPSCs 1 and DMD hiPSCs 2 EBs from day 0 to day 14 with BMP4 treatment. (Dystrophin antibody: DYS1; BMP4-treated hiPSCs 1 in 2 dimensions
(2D) culture (4 days after treatment) was used as control; α-tubulin was used as loading control)
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translation to begin downstream of the first AUG codon
in a cap-independent manner [59, 60]. A glucocorticoid-
responsive IRES in exon 5 of the DMD gene has already
been identified using reporter assays and confirmed in
vivo in mice and in vitro using human muscular cells
to induce translation initiation in exon 6 [30]. A detailed
analysis of whether the exon 5 IRES is utilized in transla-
tion of Dp412e will require a significant number of
additional experiments to address and is beyond the
scope of this current study. However, we note that in
our hands, neither dexamethasone (1 μM and 10 nM)
nor methylprednisolone (3 μM and 10 nM) treatment
succeeded in modifying Dp412e protein expression in
BMP4-treated hiPSCs 1 (data not shown). As suggested
in the original report [30], glucocorticoid action on this
IRES could be dependent on a muscular context which
would be irrelevant in our BMP4-treated model or the
Dp412e translation yield could already be at a maximum.
Even if the corresponding transcripts are different,
Dp412e protein was shown to have the same apparent
molecular weight as the dystrophin protein of a BMD
patient. Interestingly, these truncated dystrophin proteins
are expressed in two radically different contexts. However,
the mild BMD phenotype associated with this truncated
dystrophin [61] indicates that Dp412e could also be
functional. Dp412e possesses several regions along its
sequence allowing interactions with different partners
[62, 63] and even with a truncated ABD1; Dp412e could
still bind actin with ABD2 in the rod domain [64].
Dp412e was detected only in early differentiated cells,
i.e., BMP4-treated hPSCs and EBs. In a sustainable man-
ner, EBs express low level of Dp412e in the absence of
exogenous BMP4. In this particular context, BMP4
could still be involved, as endogenous BMP4 transcripts
were expressed at a basal level before and during EB
formation and further differentiation (data not shown).
In line with this hypothesis, EBs treated with BMP4
quickly express a larger stable amount of Dp412e.
Activation of BMP pathway is required for Dp412e
expression in early mesoderm precursor cells. Never-
theless, the activation of brachyury (T) is insufficient
to trigger Dp412e expression, as demonstrated by Activin
A experiments, possibly due to the associated low BMP4
endogenous level with high level of SOX2 in contrast with
the BMP4 experiments. Cells expressing Dp412e could
represent a particular type of mesoderm whose function
remains to be clarified.
Different dystrophin transcripts and isoforms are
expressed due to alternative promoters and alternative
splicing during development and/or among different
tissues in rat, mouse, human and other vertebrates [3,
5–7, 65, 66]. More specifically, in mice and human,
the splicing pattern evolves between in utero develop-
ment and the adult state in the skeletal muscle, heart and
brain [3, 4, 66, 67]. These data support altogether the pos-
sible existence of unknown dystrophin isoforms such as
Dp412e identified in this study.
Long dystrophin isoforms have already been demon-
strated to be expressed in human non-muscle cells like in
brain [68] and in melanocytes [69]. The dystrophin func-
tions in non-muscle cells were shown to be related among
others to adhesion and migratory capacity in melanocytes
[69], to neuron migration during fetal life [23], and to
modulation of synaptic function and plasticity [70]. Re-
cently, dystrophin has also been proposed as a tumor sup-
pressor through the regulation of invasion and migration in
myogenic cancers [71]. The definition of Dp412e func-
tion(s) at early developmental stages, so far not addressed,
could allow a better understanding of DMD pathophysi-
ology. As a first step, Dp412e partners can be identified by
immunoprecipitation and mass spectrophotometry studies.
Fig. 6 Exon skipping on BMP4-treated hiPSCs 1. Gel-like image data
showing exon skipping results 3 days after BMP4 treatment and 24 h
after phosphorodiamidate morpholino oligomer (PMO) transfection.
Full-length PCR product is 460 bp and exon skipped length PCR product
is 248 bp. The percentages of exon skipping obtained with the PMO
exon 53 were calculated by the Agilent 2100 Bioanalyzer software
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Furthermore, it will be interesting to verify the Dp412e ex-
pression in embryos from human and others anthropoids.
Until now, the earlier detection of dystrophin in human
embryos was described at 4 weeks of gestation by immuno-
fluorescence [72]. However, the nature of the dystrophin
isoform(s) detected in this study remains to be elucidated.
Finally, using PMO to induce exon skipping, we
validated BMP4-treated hPSCs as a model. Current cell
models are limited and cannot easily validate in parallel
the restoration of a disrupted reading frame and the
synthesis of shortened BMD-like dystrophin protein
[73, 74]. Interestingly, the simple, fast, and robust
BMP4-inducible model highlighted here, providing
large amount of a long DMD transcript and the cor-
responding protein, is already well-adapted to high-
throughput and high-content screening approaches.
Conclusions
This study validates the use of hiPSCs to analyze early
phases of human development in normal and patho-
logical contexts and has led to the discovery of a new
human embryonic 412 kDa dystrophin isoform. Decipher-
ing the regulation process(es) and the function(s) associ-
ated to this new isoform will contribute to a better
understanding of the DMD physiopathology and potential
developmental defects. Furthermore, the validation and
improvement of DMD genetic therapeutic approaches,
like exon skipping, gene editing and gene addition [10],
can be accelerated with the powerful BMP4-inducible cell
platform presented here.
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Additional file 1: Table S1. Human embryonic and induced pluripotent
stem cell line list. Details concerning the stem cell lines used in the present
study.
Additional file 2: Table S2. Primer list. Primers used in the present
study.
Additional file 3: Figure S5. BMP4-treated hiPSCs/hESCs express
dystrophin protein. (a) Western blot in six pluripotent stem cell lines
(hiPSCs 1, 3 and 4, DMD hiPSCs 1 and 3, hESCs 2) at day 4 either without
or after BMP4 treatment. (b) Western blot in hiPSCs 1 from days 0
through 4 after a single BMP4 treatment. (Dystrophin antibody: DYS1;
Muscle biopsy protein extract from a healthy individual serves as a
control, α-tubulin was used as loading control).
Additional file 4: Figure S6. Dystrophin protein expression. (a) Western
blot analyses of protein extracts from hiPSCs 1 at day 4 either without or
after BMP4 treatment using antibodies directed against different regions
of dystrophin. (Dystrophin antibodies: Manex6 (exon 6); Mandys19 (exon
21), Mandys101 (exon 40–41), Manhinge4A (exon 62), Manex7374A (exon
73–74), Mandra1 (exon 77). (b) Western blot with DYS1 antibody in three
pluripotent stem cell lines (hiPSCs 2 and 4, hESCs 2) from days 3 through
7 following BMP4 treatment. (c) Quantification of dystrophin protein
levels from the Western blots (b) in Fig. 3 and (b) in Fig. S6 (Muscle
biopsy protein extract from a healthy individual serves as a control and
α-tubulin was used as loading control).
Additional file 5: Figure S1. BMP4-treated hPSCs express a new
transient long DMD transcript. qRT-PCR of DMD transcripts using primers
specific to exons 2–3 in hiPSCs 1 and DMD hiPSCs 3 at days 3 through 7
after BMP4 treatment. For each cell line, gene expression was normalized
to GAPDH and plotted (log10 scale) relative to the expression at D0.
Additional file 6: Figure S2. 5′RACE reveals the presence of a novel
exon 1. (a, b) Two sequences found several times by 5′RACE PCR on RNA
from hiPSCs 1 three days after BMP4 treatment. In black are represented the
nucleotides found to be spliced to the DMD gene exon 2 by 5′RACE PCR,
with in (a), the 164 last nucleotides of Dp427c exon 1 and in (b), the new
exon 1. In red are the parts of the RACE sequence corresponding to DMD
gene exon 2. The black box in Dp427c sequence points out a nucleotide
that does not match with Dp427c exon 1 reference sequence. The BLAT
analyses were done on the web site https://genome.ucsc.edu.
Additional file 7: Figure S3. The new DMD exon 1 belongs to a
retrovirus-like sequence. (a) Alignment of the new exon 1 region
(highlighted in light blue) among 100 vertebrate species with the
conserved upstream/downstream sequence marked by red arrows
(https://genome.ucsc.edu). (b) Schematic representation of the approximately
8 kb region in the DMD gene that is conserved among a sub-group
of anthropoids. It is composed of simple repeats, Alu sequences and
the whole human endogenous retrovirus-like sequence HuERS-P1 (http://
www.dfam.org/entry/DF0000214) flanked by two LTR8 elements.
Additional file 8: Figure S4. In silico translation of the novel DMD
transcript. Representation of the open reading frame (ORF) resulting in
translation of the novel DMD transcript. Possible translated proteins from
this ORF are represented in red. The largest predicted protein is composed
of 3562 amino acids (≈412 kDa) (http://web.expasy.org/translate).
Additional file 9: Figure S7. Dp412e expression study. Fold change
obtained by quantitative RT-PCR using primers specific for Dp427m, Dp427c
and Dp412e on RNAs from either human adult tissues, 7–11 weeks old fetuses
or human 25–40 weeks old fetal tissues. Gene expression was normalized to
UBC and relative to BMP4-treated hiPSCs 1 at day 3.
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